Literature DB >> 20602082

Multifunctional proteins bridge mitosis with motility and cancer with inflammation and arthritis.

Jihong Jiang1, Rosaely Casalegno-Garduno, Helen Chen, Anita Schmitt, Michael Schmitt, Christopher A Maxwell.   

Abstract

While most secreted proteins contain defined signal peptides that direct their extracellular transport through the ER-Golgi pathway, nonclassical transport of leaderless peptides/proteins was first described 20 years ago and the mechanisms responsible for unconventional export of such proteins have been thoroughly reviewed. In addition to directed nonclassical secretion, a number of leaderless secreted proteins have been classified as damage-associated molecular-pattern (DAMP) molecules, which are nuclear or cytoplasmic proteins that, under necrotic or apoptotic conditions, are released outside the cell and function as proinflammatory signals. A strong association between persistent release of DAMPs, chronic inflammation, and the hypoxic tumor microenvironment has been proposed. Thus, protein localization and function can change fundamentally from intracellular to extracellular compartments, often under conditions of inflammation, cancer, and arthritis. If we are truly to understand, model, and treat such biological states, it will be important to investigate these multifunctional proteins and their contribution to degenerative diseases. Here, we will focus our discussion on intracellular proteins, both cytoplasmic and nuclear, that play critical extracellular roles. In particular, the multifunctional nature of HMMR/RHAMM and survivin will be highlighted and compared, as these molecules are the subject of extensive biological and therapeutic investigations within hematology and oncology fields. For these and other genes/proteins, we will highlight points of structural and functional intersection during cellular division and differentiation, as well as states associated with cancer, such as tumor-initiation and epithelial-to-mesenchymal transition (EMT). Finally, we will discuss the potential targeting of these proteins for improved therapeutic outcomes within these degenerative disorders. Our goal is to highlight a number of commonalities among these multifunctional proteins for better understanding of their putative roles in tumor initiation, inflammation, arthritis, and cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20602082      PMCID: PMC5763930          DOI: 10.1100/tsw.2010.141

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  13 in total

1.  Receptor for hyaluronan mediated motility (RHAMM/HMMR) is a novel target for promoting subcutaneous adipogenesis.

Authors:  S B Bahrami; C Tolg; T Peart; C Symonette; M Veiseh; J U Umoh; D W Holdsworth; J B McCarthy; L G Luyt; M J Bissell; A Yazdani; E A Turley
Journal:  Integr Biol (Camb)       Date:  2017-02-20       Impact factor: 2.192

2.  CD44 and RHAMM hyaluronan receptors in human ocular surface inflammation.

Authors:  Laura García-Posadas; Laura Contreras-Ruiz; Isabel Arranz-Valsero; Antonio López-García; Margarita Calonge; Yolanda Diebold
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-06-12       Impact factor: 3.117

3.  Identification, design and synthesis of tubulin-derived peptides as novel hyaluronan mimetic ligands for the receptor for hyaluronan-mediated motility (RHAMM/HMMR).

Authors:  Kenneth Virgel N Esguerra; Cornelia Tolg; Natalia Akentieva; Matthew Price; Choi-Fong Cho; John D Lewis; James B McCarthy; Eva A Turley; Leonard G Luyt
Journal:  Integr Biol (Camb)       Date:  2015-10-12       Impact factor: 2.192

4.  The oncofetal gene survivin is re-expressed in osteoarthritis and is required for chondrocyte proliferation in vitro.

Authors:  Philipp Lechler; Sanjeevi Balakrishnan; Jens Schaumburger; Susanne Grässel; Clemens Baier; Joachim Grifka; Rainer H Straub; Tobias Renkawitz
Journal:  BMC Musculoskelet Disord       Date:  2011-07-05       Impact factor: 2.362

5.  Relationships between predicted moonlighting proteins, human diseases, and comorbidities from a network perspective.

Authors:  Andreas Zanzoni; Charles E Chapple; Christine Brun
Journal:  Front Physiol       Date:  2015-06-23       Impact factor: 4.566

Review 6.  Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer.

Authors:  Suniti Misra; Vincent C Hascall; Roger R Markwald; Shibnath Ghatak
Journal:  Front Immunol       Date:  2015-05-06       Impact factor: 7.561

7.  The cytoskeletal protein RHAMM and ERK1/2 activity maintain the pluripotency of murine embryonic stem cells.

Authors:  Jihong Jiang; Pooja Mohan; Christopher A Maxwell
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

Review 8.  Cancer microenvironment and inflammation: role of hyaluronan.

Authors:  Dragana Nikitovic; Maria Tzardi; Aikaterini Berdiaki; Aristidis Tsatsakis; George N Tzanakakis
Journal:  Front Immunol       Date:  2015-04-14       Impact factor: 7.561

Review 9.  Cardiovascular Effects Mediated by HMMR and CD44.

Authors:  Kinga Jaskuła; Mariusz Sacharczuk; Zbigniew Gaciong; Dominik S Skiba
Journal:  Mediators Inflamm       Date:  2021-07-10       Impact factor: 4.711

10.  Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.

Authors:  Pooja Mohan; Joan Castellsague; Jihong Jiang; Kristi Allen; Helen Chen; Oksana Nemirovsky; Melanie Spyra; Kaiji Hu; Lan Kluwe; Miguel Angel Pujana; Alberto Villanueva; Victor F Mautner; Jonathan J Keats; Sandra E Dunn; Conxi Lazaro; Christopher A Maxwell
Journal:  Oncotarget       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.